Manufacturing

Feliza Mirasol is the science editor for 

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Articles

Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.

Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 2

Part 1—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius discuss key issues affecting the development of emerging biotherapies.

Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 1 

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

A new GMP facility in Raleigh, NC, and a starting materials facility in Paris, France, give Cellectis end-to-end, in-house manufacturing capacity for its UCART product candidates.  

Cellectis Opens GMP Manufacturing Facility

Avid Bioservices is building a viral vector development and manufacturing facility near its existing biologics manufacturing facility in California. 

Avid Bioservices Expands into Viral Vector Development and Manufacturing Services

The $3 million investment will go towards various projects investigating key product attributes for therapeutic proteins.

NIIMBL Invests $3 Million in Six Biopharmaceutical Manufacturing Products

Repligen and Navigo’s novel ligand could be the first to address antibody aggregation in low pH elution buffers.

Repligen and Navigo GmbH Launch Industry-First Protein A Ligand for Purification of pH-Sensitive Antibodies

AGC Biologics is expanding manufacturing capacity at its Heidelberg, Germany, facility for plasmid DNA and messenger RNA.

AGC Bio Boosts Manufacturing Capacity for pDNA and mRNA at Heidelberg Facility

Corning’s new Ascent fixed bed reactor (FBR) system is an automated bioproduction platform designed to significantly improve yields and reduce bioproduction costs.

Corning’s New Cell and Gene Therapy Platform Demonstrates Large-Scale Bioproduction

The collaboration will focus on the interactions between WTX-124 indukine and KEYTRUDA (pembrolizumab).

Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck

Artiva Biotherapeutics’s new R&D and GMP manufacturing center in San Diego, Calif., for NK cell therapies is expected to open in 2022.

Manufacturing, Cell Therapies